Comparative Pharmacology
Head-to-head clinical analysis: MANNITOL 15 IN PLASTIC CONTAINER versus OSMITROL 15 IN WATER IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANNITOL 15 IN PLASTIC CONTAINER versus OSMITROL 15 IN WATER IN PLASTIC CONTAINER.
MANNITOL 15% IN PLASTIC CONTAINER vs OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mannitol is an osmotic diuretic that increases plasma osmolality, thereby drawing water from extravascular spaces into the plasma and reducing intracranial pressure. It also increases renal tubular osmotic pressure, inhibiting water reabsorption and promoting diuresis.
Osmotically active agent that increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing cerebral edema and intraocular pressure.
Intravenous: 50-100 g (1-2 g/kg) as a 15-25% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. For oliguric acute kidney injury: test dose of 0.2 g/kg IV over 3-5 minutes; if urine output >50 mL/hr, administer 50-100 g as 15-20% solution over 2-6 hours.
1.5-2 g/kg intravenous infusion over 30-60 minutes every 6-8 hours as needed for reduction of intracranial pressure or cerebral edema.
None Documented
None Documented
Terminal elimination half-life approximately 0.5–1 hour in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Terminal half-life: 0.25–1.5 hours (15–90 minutes) in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Renal: >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination (<2%).
Renal: >90% unchanged by glomerular filtration; minimal tubular reabsorption or secretion. <10% metabolized in liver (negligible).
Category A/B
Category C
Osmotic Diuretic
Osmotic Diuretic